Celcuity Inc (CELC)

$92.47 +3.52 (3.96%)
Market Cap 4.46B
Revenue (ttm) 0.00
Net Income (ttm) -177.04M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin 0.00%
Debt to Equity Ratio 2.39
Volume 3,701,477
Avg Vol 977,660
Day's Range N/A - N/A
Shares Out 48.77M
Stochastic %K 38%
Beta 0.10
Analysts Strong Sell
Price Target $168.54

Company Profile

Celcuity Inc., a clinical-stage biotechnology company, focuses on the development of targeted therapies for the treatment of various solid tumors in the United States. The company's lead drug candidate includes Gedatolisib, which selectively targets various Class I isoforms of phosphatidylinositol-3-kinase (PI3K) and the two mechanistic targets of rapamycin (mTOR) sub-complexes, mTORC1 and mTORC2 to treat patients with hormone receptor positive (HR+), human epidermal growth factor receptor 2 neg...

Industry: Biotechnology
Sector: Healthcare
Phone: 763 392 0767
Address:
16305 36th Avenue North, Suite 100, Minneapolis, United States
SwingTraderPro1
SwingTraderPro1 Jun. 4 at 8:14 PM
$CELC Here’s a classic Bio gap trade setup. Pulled down on the notes offering despite killer breast cancer data, but the offering is now closed. That’s the kind of shakeout that sets up a clean move back up. Keep an eye on July 17 PDUFA as the next catalyst. First target is 100, and if momentum stays, skies are clear well above that. Perfect setup for anyone who loves catching gaps after a shakeout.
0 · Reply
TheTarkioTrader
TheTarkioTrader Jun. 4 at 8:00 PM
$CELC OK it was nice to get all that out-of-the-way..
0 · Reply
ripster47
ripster47 Jun. 4 at 6:40 PM
$CELC ⚡️ Another beautiful Bio Gap Trade Setup vs lows Down on Notes offering with amazing breast cancer data Offering closed we start move back up! Catylyst in July 17 PDUFA for runup Our first target 100 and clear skies over that https://x.com/TenetCharts
0 · Reply
chartistmind
chartistmind Jun. 4 at 2:25 PM
$CELC
0 · Reply
TheTarkioTrader
TheTarkioTrader Jun. 4 at 1:37 PM
$CELC added @$86.37
0 · Reply
TheTarkioTrader
TheTarkioTrader Jun. 4 at 12:38 PM
$CELC
0 · Reply
Uncle_Baby_Billy
Uncle_Baby_Billy Jun. 4 at 11:39 AM
$CELC
0 · Reply
CharlieeMungerTWITS
CharlieeMungerTWITS Jun. 4 at 10:05 AM
$CELC holy crap. $127 and they increased it to $625 million of convertible notes. That tells you there was significant institutional demand for the paper!!! $1B war chest now to commercialize !!
1 · Reply
TheTarkioTrader
TheTarkioTrader Jun. 4 at 7:10 AM
$CELC The market got the details. Upsized to $460M, only 0.25% interest, and a conversion price around $127/share. That’s a meaningful premium to where CELC trades today and suggests strong institutional demand. The financing overhang is largely removed, Oxford debt gets addressed, and the company is funded to advance gedatolisib. Not the terms you’d expect if institutions thought the data wasn’t real.
0 · Reply
Dark_Horse_Investments
Dark_Horse_Investments Jun. 4 at 3:39 AM
$CELC $124.53 coversion price and raising $500 M not $400 M as previously reported. woah what muscling by CEO sullivan ! https://ir.celcuity.com/news-releases/news-release-details/celcuity-inc-announces-pricing-upsized-public-offering-0250
1 · Reply
Latest News on CELC
Celcuity Slides: FY 2026

Jun 10, 2026, 8:00 AM EDT - Just now

Celcuity Slides: FY 2026

Celcuity Transcript: Jefferies Global Healthcare Conference 2026

Jun 4, 2026, 1:25 PM EDT - 4 hours ago

Celcuity Transcript: Jefferies Global Healthcare Conference 2026

Celcuity prices $500M convertible senior note offering

2026-06-04T11:42:59.000Z - 10 hours ago

Celcuity prices $500M convertible senior note offering

Celcuity Inc. Announces Pricing of Upsized Public Offering of 0.250% Convertible Senior Notes Due 2032

Jun 3, 2026, 10:13 PM EDT - 19 hours ago

Celcuity Inc. Announces Pricing of Upsized Public Offering of 0.250% Convertible Senior Notes Due 2032

Celcuity price target lowered to $171 from $189 at Craig-Hallum

2026-06-03T15:14:03.000Z - 1 day ago

Celcuity price target lowered to $171 from $189 at Craig-Hallum

Celcuity price target lowered to $166 from $183 at Wells Fargo

2026-06-03T11:46:12.000Z - 1 day ago

Celcuity price target lowered to $166 from $183 at Wells Fargo

Celcuity Inc. Announces Public Offering of Convertible Senior Notes Due 2032

Jun 3, 2026, 7:19 AM EDT - 1 day ago

Celcuity Inc. Announces Public Offering of Convertible Senior Notes Due 2032

Celcuity price target lowered to $145 from $185 at H.C. Wainwright

2026-06-03T10:21:27.000Z - 1 day ago

Celcuity price target lowered to $145 from $185 at H.C. Wainwright

Celcuity plunges after experimental breast cancer treatment data disappoints

Jun 2, 2026, 1:20 PM EDT - 2 days ago

Celcuity plunges after experimental breast cancer treatment data disappoints

Celcuity falls -23.5%

2026-06-02T16:20:25.000Z - 2 days ago

Celcuity falls -23.5%

Celcuity falls -22.2%

2026-06-02T16:08:41.000Z - 2 days ago

Celcuity falls -22.2%

Celcuity reports efficacy, safety data from PIK3CA mutant cohort of VIKTORIA-1

2026-06-02T14:59:25.000Z - 2 days ago

Celcuity reports efficacy, safety data from PIK3CA mutant cohort of VIKTORIA-1

Celcuity's Gedatolisib Combination Regimens Doubled the Likelihood of Survival without Disease Progression or Death Compared to Alpelisib plus Fulvestrant in the PIK3CA Mutant Cohort of the Pivotal Phase 3 VIKTORIA-1 Trial in Patients with HR+/HER2- Advanced Breast Cancer

Jun 2, 2026, 8:25 AM EDT - 2 days ago

Celcuity's Gedatolisib Combination Regimens Doubled the Likelihood of Survival without Disease Progression or Death Compared to Alpelisib plus Fulvestrant in the PIK3CA Mutant Cohort of the Pivotal Phase 3 VIKTORIA-1 Trial in Patients with HR+/HER2- Advanced Breast Cancer

Celcuity Transcript: Study result

Jun 2, 2026, 8:00 AM EDT - 2 days ago

Celcuity Transcript: Study result

Celcuity Press release: Study result

Jun 2, 2026, 8:00 AM EDT - 2 days ago

Celcuity Press release: Study result

Celcuity Slides: Study result

Jun 2, 2026, 8:00 AM EDT - 2 days ago

Celcuity Slides: Study result

Celcuity to Hold Conference Call to Discuss Results for the PIK3CA Mutant Cohort of the Phase 3 VIKTORIA-1 Clinical Trial of Gedatolisib Regimens in HR+/HER- Advanced Breast Cancer on June 2, 2026

Jun 1, 2026, 8:30 AM EDT - 3 days ago

Celcuity to Hold Conference Call to Discuss Results for the PIK3CA Mutant Cohort of the Phase 3 VIKTORIA-1 Clinical Trial of Gedatolisib Regimens in HR+/HER- Advanced Breast Cancer on June 2, 2026

Celcuity To Participate in Upcoming Investor Conferences

May 28, 2026, 8:30 AM EDT - 7 days ago

Celcuity To Participate in Upcoming Investor Conferences

Celcuity price target raised to $185 from $165 at H.C. Wainwright

2026-05-18T10:05:06.000Z - 17 days ago

Celcuity price target raised to $185 from $165 at H.C. Wainwright

Celcuity price target raised to $175 from $150 at Stifel

2026-05-15T13:21:29.000Z - 20 days ago

Celcuity price target raised to $175 from $150 at Stifel

Celcuity price target raised to $183 from $150 at Wells Fargo

2026-05-15T11:00:19.000Z - 20 days ago

Celcuity price target raised to $183 from $150 at Wells Fargo

Celcuity reports Q1 adjusted EPS (86c) vs. (81c) last year

2026-05-14T21:44:38.000Z - 21 days ago

Celcuity reports Q1 adjusted EPS (86c) vs. (81c) last year

Celcuity Earnings Call Transcript: Q1 2026

May 14, 2026, 4:30 PM EDT - 21 days ago

Celcuity Earnings Call Transcript: Q1 2026

Celcuity Earnings release: Q1 2026

May 14, 2026, 4:30 PM EDT - 21 days ago

Celcuity Earnings release: Q1 2026

Celcuity Quarterly report: Q1 2026

May 14, 2026, 4:30 PM EDT - 21 days ago

Celcuity Quarterly report: Q1 2026

Notable companies reporting after market close

2026-05-14T20:12:10.000Z - 21 days ago

Notable companies reporting after market close

AMAT BOOT FIG

Celcuity Inc. Reports Release of First Quarter 2026 Financial Results and Provides Corporate Update

May 14, 2026, 4:01 PM EDT - 21 days ago

Celcuity Inc. Reports Release of First Quarter 2026 Financial Results and Provides Corporate Update

Celcuity announces amendments to VIKTORIA-2 clinical trial of gedatolisib

2026-05-14T14:18:58.000Z - 21 days ago

Celcuity announces amendments to VIKTORIA-2 clinical trial of gedatolisib

Celcuity's Phase 3 VIKTORIA-2 Trial of Gedatolisib as a First-Line Treatment for HR+/HER2- Advanced Breast Cancer Expanding to Include Endocrine-Sensitive Patients

May 14, 2026, 7:30 AM EDT - 21 days ago

Celcuity's Phase 3 VIKTORIA-2 Trial of Gedatolisib as a First-Line Treatment for HR+/HER2- Advanced Breast Cancer Expanding to Include Endocrine-Sensitive Patients

Celcuity Schedules Release of First Quarter 2026 Financial Results and Webcast/Conference Call

May 7, 2026, 8:00 AM EDT - 4 weeks ago

Celcuity Schedules Release of First Quarter 2026 Financial Results and Webcast/Conference Call

Celcuity rises 18.4%

2026-05-04T16:06:29.000Z - 4 weeks ago

Celcuity rises 18.4%

Celcuity rises 17.1%

2026-05-04T14:25:21.000Z - 4 weeks ago

Celcuity rises 17.1%

Celcuity price target raised to $189 from $141 at Craig-Hallum

2026-05-04T13:49:08.000Z - 4 weeks ago

Celcuity price target raised to $189 from $141 at Craig-Hallum

Celcuity's Phase 3 VIKTORIA-1 Trial Achieves Primary Endpoint With Clinically Meaningful Improvement in Progression-Free Survival in PIK3CA Mutant Cohort

May 1, 2026, 5:03 PM EDT - 4 weeks ago

Celcuity's Phase 3 VIKTORIA-1 Trial Achieves Primary Endpoint With Clinically Meaningful Improvement in Progression-Free Survival in PIK3CA Mutant Cohort

Celcuity Proxy statement: Proxy filing

Apr 2, 2026, 8:00 AM EDT - 2 months ago

Celcuity Proxy statement: Proxy filing

Celcuity Proxy statement: Proxy filing

Apr 2, 2026, 8:00 AM EDT - 2 months ago

Celcuity Proxy statement: Proxy filing

Celcuity Earnings Call Transcript: Q4 2025

Mar 25, 2026, 4:30 PM EDT - 2 months ago

Celcuity Earnings Call Transcript: Q4 2025

Celcuity Annual report: Q4 2025

Mar 25, 2026, 4:30 PM EDT - 2 months ago

Celcuity Annual report: Q4 2025

Celcuity Earnings release: Q4 2025

Mar 25, 2026, 4:30 PM EDT - 2 months ago

Celcuity Earnings release: Q4 2025

Celcuity Inc. Reports Release of Fourth Quarter and Full Year 2025 Financial Results and Provides Corporate Update

Mar 25, 2026, 4:01 PM EDT - 2 months ago

Celcuity Inc. Reports Release of Fourth Quarter and Full Year 2025 Financial Results and Provides Corporate Update

Celcuity Schedules Release of Fourth Quarter and Full Year 2025 Financial Results and Webcast/Conference Call

Mar 18, 2026, 8:00 AM EDT - 2 months ago

Celcuity Schedules Release of Fourth Quarter and Full Year 2025 Financial Results and Webcast/Conference Call

Celcuity Transcript: Leerink Global Healthcare Conference 2026

Mar 10, 2026, 2:20 PM EDT - 3 months ago

Celcuity Transcript: Leerink Global Healthcare Conference 2026

Celcuity Announces Publication of Results from PIK3CA Wild-Type Cohort of Phase 3 VIKTORIA-1 Study of Gedatolisib Regimens in HR+/HER2- Advanced Breast Cancer in Journal of Clinical Oncology

Mar 9, 2026, 5:42 PM EDT - 3 months ago

Celcuity Announces Publication of Results from PIK3CA Wild-Type Cohort of Phase 3 VIKTORIA-1 Study of Gedatolisib Regimens in HR+/HER2- Advanced Breast Cancer in Journal of Clinical Oncology

Celcuity Transcript: TD Cowen 46th Annual Health Care Conference

Mar 4, 2026, 10:30 AM EST - 3 months ago

Celcuity Transcript: TD Cowen 46th Annual Health Care Conference

Celcuity Appoints Charles Romp to its Board of Directors

Feb 12, 2026, 4:05 PM EST - 4 months ago

Celcuity Appoints Charles Romp to its Board of Directors

Celcuity Transcript: Guggenheim Securities Emerging Outlook: Biotech Summit 2026

Feb 11, 2026, 9:30 AM EST - 4 months ago

Celcuity Transcript: Guggenheim Securities Emerging Outlook: Biotech Summit 2026

Celcuity to Present at Upcoming Guggenheim Emerging Outlook: Biotech Summit 2026

Feb 4, 2026, 7:05 AM EST - 4 months ago

Celcuity to Present at Upcoming Guggenheim Emerging Outlook: Biotech Summit 2026

These 20 stocks are strong choices for momentum investors

Jan 22, 2026, 10:26 AM EST - 4 months ago

These 20 stocks are strong choices for momentum investors

BE COGT FBYD FRGE INBX KOD LITE

Celcuity Announces FDA Acceptance of New Drug Application for Gedatolisib in HR+/HER2-/PIK3CA Wild-Type Advanced Breast Cancer

Jan 20, 2026, 7:30 AM EST - 4 months ago

Celcuity Announces FDA Acceptance of New Drug Application for Gedatolisib in HR+/HER2-/PIK3CA Wild-Type Advanced Breast Cancer

Celcuity Presents Updated Results from the PIK3CA Wild-Type Cohort of the Phase 3 VIKTORIA-1 Trial at the 2025 San Antonio Breast Cancer Symposium

Dec 11, 2025, 2:35 PM EST - 6 months ago

Celcuity Presents Updated Results from the PIK3CA Wild-Type Cohort of the Phase 3 VIKTORIA-1 Trial at the 2025 San Antonio Breast Cancer Symposium

Celcuity Transcript: Evercore ISI 8th Annual HealthCONx Conference

Dec 3, 2025, 7:30 AM EST - 6 months ago

Celcuity Transcript: Evercore ISI 8th Annual HealthCONx Conference

Celcuity to Present Updated Data from the PIK3CA Wild-Type Cohort of the Phase 3 VIKTORIA-1 Trial at the 2025 San Antonio Breast Cancer Symposium

Nov 26, 2025, 4:05 PM EST - 6 months ago

Celcuity to Present Updated Data from the PIK3CA Wild-Type Cohort of the Phase 3 VIKTORIA-1 Trial at the 2025 San Antonio Breast Cancer Symposium

Celcuity To Present at Upcoming 8th Annual Evercore Healthcare Conference

Nov 26, 2025, 7:05 AM EST - 6 months ago

Celcuity To Present at Upcoming 8th Annual Evercore Healthcare Conference

Celcuity Announces Completion of Submission of Its New Drug Application to the U.S. FDA for Gedatolisib in HR+/HER2-/PIK3CA Wild-Type Advanced Breast Cancer

Nov 17, 2025, 4:05 PM EST - 7 months ago

Celcuity Announces Completion of Submission of Its New Drug Application to the U.S. FDA for Gedatolisib in HR+/HER2-/PIK3CA Wild-Type Advanced Breast Cancer

Celcuity Earnings Call Transcript: Q3 2025

Nov 12, 2025, 4:30 PM EST - 7 months ago

Celcuity Earnings Call Transcript: Q3 2025

Celcuity Quarterly report: Q3 2025

Nov 12, 2025, 4:30 PM EST - 7 months ago

Celcuity Quarterly report: Q3 2025

Celcuity Earnings release: Q3 2025

Nov 12, 2025, 4:30 PM EST - 7 months ago

Celcuity Earnings release: Q3 2025

Celcuity Inc. Reports Third Quarter 2025 Financial Results and Provides Corporate Update

Nov 12, 2025, 4:01 PM EST - 7 months ago

Celcuity Inc. Reports Third Quarter 2025 Financial Results and Provides Corporate Update

Celcuity Transcript: Stifel 2025 Healthcare Conference

Nov 11, 2025, 10:00 AM EST - 7 months ago

Celcuity Transcript: Stifel 2025 Healthcare Conference

Celcuity Inc. Schedules Release of Third Quarter 2025 Financial Results and Webcast/Conference Call

Nov 5, 2025, 7:05 AM EST - 7 months ago

Celcuity Inc. Schedules Release of Third Quarter 2025 Financial Results and Webcast/Conference Call

Celcuity To Present at Upcoming Stifel 2025 Healthcare Conference

Nov 4, 2025, 7:05 AM EST - 7 months ago

Celcuity To Present at Upcoming Stifel 2025 Healthcare Conference

CRMD, RANI, CELC, RAPT: four biotech stocks flying high today and why

Oct 20, 2025, 9:42 AM EDT - 8 months ago

CRMD, RANI, CELC, RAPT: four biotech stocks flying high today and why

CRMD RANI RAPT

Celcuity Transcript: Study Result

Oct 20, 2025, 8:00 AM EDT - 8 months ago

Celcuity Transcript: Study Result

Celcuity Press release: Study Result

Oct 20, 2025, 8:00 AM EDT - 8 months ago

Celcuity Press release: Study Result

Celcuity Slides: Study Result

Oct 20, 2025, 8:00 AM EDT - 8 months ago

Celcuity Slides: Study Result

Detailed Results from PIK3CA Wild-Type Cohort of Phase 3 VIKTORIA-1 Trial Presented at 2025 ESMO Congress Demonstrate Potential for Gedatolisib Regimens to be Practice Changing for Patients with HR+/HER2- Advanced Breast Cancer

Oct 18, 2025, 4:30 AM EDT - 8 months ago

Detailed Results from PIK3CA Wild-Type Cohort of Phase 3 VIKTORIA-1 Trial Presented at 2025 ESMO Congress Demonstrate Potential for Gedatolisib Regimens to be Practice Changing for Patients with HR+/HER2- Advanced Breast Cancer

Celcuity Presents Updated Data at the 2025 ESMO Congress from Phase 1 Study Evaluating Gedatolisib Plus Darolutamide in Men with Metastatic Castration Resistant Prostate Cancer (“mCRPC”)

Oct 18, 2025, 4:30 AM EDT - 8 months ago

Celcuity Presents Updated Data at the 2025 ESMO Congress from Phase 1 Study Evaluating Gedatolisib Plus Darolutamide in Men with Metastatic Castration Resistant Prostate Cancer (“mCRPC”)

Celcuity Provides Update on Status of the PIK3CA Mutated Cohort of Phase 3 VIKTORIA-1 Trial and Releases Additional Data Analysis From Phase 1b Clinical Trial

Oct 18, 2025, 4:30 AM EDT - 8 months ago

Celcuity Provides Update on Status of the PIK3CA Mutated Cohort of Phase 3 VIKTORIA-1 Trial and Releases Additional Data Analysis From Phase 1b Clinical Trial

Celcuity Slides: Corporate Presentation

Oct 16, 2025, 7:00 AM EDT - 8 months ago

Celcuity Slides: Corporate Presentation

Celcuity to Present Results from the Pivotal Phase 3 VIKTORIA-1 Trial at the 2025 European Society for Medical Oncology (ESMO) Congress

Sep 22, 2025, 9:15 AM EDT - 9 months ago

Celcuity to Present Results from the Pivotal Phase 3 VIKTORIA-1 Trial at the 2025 European Society for Medical Oncology (ESMO) Congress

Celcuity Announces Upsized Senior Secured Term Loan Facility of $500 Million with Innovatus Capital Partners and Oxford Finance

Sep 9, 2025, 4:01 PM EDT - 9 months ago

Celcuity Announces Upsized Senior Secured Term Loan Facility of $500 Million with Innovatus Capital Partners and Oxford Finance

Celcuity to Initiate NDA Submission of Gedatolisib in PIK3CA Wild-Type Cohort in HR+/HER2- Advanced Breast Cancer Under FDA's Real-Time Oncology Review Program

Aug 27, 2025, 4:05 PM EDT - 10 months ago

Celcuity to Initiate NDA Submission of Gedatolisib in PIK3CA Wild-Type Cohort in HR+/HER2- Advanced Breast Cancer Under FDA's Real-Time Oncology Review Program

Celcuity Earnings Call Transcript: Q2 2025

Aug 14, 2025, 4:30 PM EDT - 10 months ago

Celcuity Earnings Call Transcript: Q2 2025

Celcuity Earnings release: Q2 2025

Aug 14, 2025, 4:30 PM EDT - 10 months ago

Celcuity Earnings release: Q2 2025

Celcuity Quarterly report: Q2 2025

Aug 14, 2025, 4:30 PM EDT - 10 months ago

Celcuity Quarterly report: Q2 2025

Celcuity Inc. Reports Second Quarter 2025 Financial Results and Provides Corporate Update

Aug 14, 2025, 4:01 PM EDT - 10 months ago

Celcuity Inc. Reports Second Quarter 2025 Financial Results and Provides Corporate Update

Celcuity Inc. Schedules Release of Second Quarter 2025 Financial Results and Webcast/Conference Call

Aug 7, 2025, 7:05 AM EDT - 10 months ago

Celcuity Inc. Schedules Release of Second Quarter 2025 Financial Results and Webcast/Conference Call

Celcuity Inc. Announces Pricing of Concurrent Public Offerings of 2.750% Convertible Senior Notes Due 2031 and Common Stock and Pre-Funded Warrants

Jul 30, 2025, 6:30 AM EDT - 11 months ago

Celcuity Inc. Announces Pricing of Concurrent Public Offerings of 2.750% Convertible Senior Notes Due 2031 and Common Stock and Pre-Funded Warrants

Celcuity: What's Happening With CELC Stock?

Jul 29, 2025, 6:40 AM EDT - 11 months ago

Celcuity: What's Happening With CELC Stock?

Celcuity Inc. Announces Concurrent Public Offerings of Convertible Senior Notes Due 2031 and Common Stock

Jul 28, 2025, 4:02 PM EDT - 11 months ago

Celcuity Inc. Announces Concurrent Public Offerings of Convertible Senior Notes Due 2031 and Common Stock

Celcuity shares skyrocket as breast cancer drug combo shows dramatic Phase 3 success

Jul 28, 2025, 3:02 PM EDT - 11 months ago

Celcuity shares skyrocket as breast cancer drug combo shows dramatic Phase 3 success

Celcuity Transcript: Status Update

Jul 28, 2025, 8:00 AM EDT - 11 months ago

Celcuity Transcript: Status Update

Celcuity Slides: Status Update

Jul 28, 2025, 8:00 AM EDT - 11 months ago

Celcuity Slides: Status Update

Celcuity's triple cancer drug combo tops AstraZeneca's in cutting progression in study

Jul 28, 2025, 7:49 AM EDT - 11 months ago

Celcuity's triple cancer drug combo tops AstraZeneca's in cutting progression in study

Celcuity Announces Clinically Meaningful Improvement in Both Progression-Free Survival (“PFS”) Primary Endpoints from PIK3CA Wild-Type Cohort of Phase 3 VIKTORIA-1 Trial

Jul 28, 2025, 7:00 AM EDT - 11 months ago

Celcuity Announces Clinically Meaningful Improvement in Both Progression-Free Survival (“PFS”) Primary Endpoints from PIK3CA Wild-Type Cohort of Phase 3 VIKTORIA-1 Trial

Celcuity to Announce Topline Results for the PIK3CA Wild-Type Cohort from Phase 3 VIKTORIA-1 Trial in HR+/HER2- Advanced Breast Cancer

Jul 25, 2025, 4:05 PM EDT - 11 months ago

Celcuity to Announce Topline Results for the PIK3CA Wild-Type Cohort from Phase 3 VIKTORIA-1 Trial in HR+/HER2- Advanced Breast Cancer

Celcuity Announces First Patient Dosed in Phase 3 VIKTORIA-2 Clinical Trial of Gedatolisib as a First-Line Treatment for HR+/HER2- Advanced Breast Cancer

Jul 24, 2025, 4:01 PM EDT - 11 months ago

Celcuity Announces First Patient Dosed in Phase 3 VIKTORIA-2 Clinical Trial of Gedatolisib as a First-Line Treatment for HR+/HER2- Advanced Breast Cancer

Celcuity Announces Issuance of New Patent for Gedatolisib that Extends Patent Exclusivity into 2042

Jul 14, 2025, 7:05 AM EDT - 11 months ago

Celcuity Announces Issuance of New Patent for Gedatolisib that Extends Patent Exclusivity into 2042

Celcuity Reports Clinical Data from Two Early Phase Studies of Gedatolisib

Jun 30, 2025, 7:05 AM EDT - 1 year ago

Celcuity Reports Clinical Data from Two Early Phase Studies of Gedatolisib

Celcuity Slides: Corporate Presentation

Jun 30, 2025, 7:00 AM EDT - 1 year ago

Celcuity Slides: Corporate Presentation

Celcuity Transcript: Jefferies Global Healthcare Conference 2025

Jun 5, 2025, 7:35 AM EDT - 1 year ago

Celcuity Transcript: Jefferies Global Healthcare Conference 2025

Celcuity Transcript: TD Cowen's 6th Annual Oncology Innovation Summit

May 28, 2025, 9:30 AM EDT - 1 year ago

Celcuity Transcript: TD Cowen's 6th Annual Oncology Innovation Summit

Celcuity To Present at Upcoming TD Cowen and Jefferies Investor Conferences

May 21, 2025, 7:05 AM EDT - 1 year ago

Celcuity To Present at Upcoming TD Cowen and Jefferies Investor Conferences

Celcuity Earnings Call Transcript: Q1 2025

May 14, 2025, 4:30 PM EDT - 1 year ago

Celcuity Earnings Call Transcript: Q1 2025

Celcuity Earnings release: Q1 2025

May 14, 2025, 4:30 PM EDT - 1 year ago

Celcuity Earnings release: Q1 2025

Celcuity Quarterly report: Q1 2025

May 14, 2025, 4:30 PM EDT - 1 year ago

Celcuity Quarterly report: Q1 2025

Celcuity Inc. Reports First Quarter 2025 Financial Results and Provides Corporate Update

May 14, 2025, 4:01 PM EDT - 1 year ago

Celcuity Inc. Reports First Quarter 2025 Financial Results and Provides Corporate Update

Celcuity Inc. Schedules Release of First Quarter 2025 Financial Results and Webcast/Conference Call

May 7, 2025, 7:05 AM EDT - 1 year ago

Celcuity Inc. Schedules Release of First Quarter 2025 Financial Results and Webcast/Conference Call

Celcuity Transcript: 24th Annual Needham Virtual Healthcare Conference

Apr 10, 2025, 11:00 AM EDT - 1 year ago

Celcuity Transcript: 24th Annual Needham Virtual Healthcare Conference

Celcuity Transcript: Stifel 2025 Virtual Targeted Oncology Forum

Apr 9, 2025, 10:00 AM EDT - 1 year ago

Celcuity Transcript: Stifel 2025 Virtual Targeted Oncology Forum

Celcuity Proxy statement: Proxy Filing

Apr 1, 2025, 8:00 AM EDT - 1 year ago

Celcuity Proxy statement: Proxy Filing

Celcuity Proxy statement: Proxy Filing

Apr 1, 2025, 8:00 AM EDT - 1 year ago

Celcuity Proxy statement: Proxy Filing

Celcuity To Present at Upcoming Needham and Stifel Investor Conferences

Apr 1, 2025, 7:05 AM EDT - 1 year ago

Celcuity To Present at Upcoming Needham and Stifel Investor Conferences

Celcuity Inc. Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Corporate Update

Mar 31, 2025, 4:01 PM EDT - 1 year ago

Celcuity Inc. Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Corporate Update

Celcuity Earnings Call Transcript: Q4 2024

Mar 31, 2025, 2:00 AM EDT - 1 year ago

Celcuity Earnings Call Transcript: Q4 2024

Celcuity Annual report: Q4 2024

Mar 31, 2025, 2:00 AM EDT - 1 year ago

Celcuity Annual report: Q4 2024

Celcuity Earnings release: Q4 2024

Mar 31, 2025, 2:00 AM EDT - 1 year ago

Celcuity Earnings release: Q4 2024

Celcuity Inc. Schedules Release of Fourth Quarter and Full Year 2024 Financial Results and Webcast/Conference Call

Mar 24, 2025, 7:05 AM EDT - 1 year ago

Celcuity Inc. Schedules Release of Fourth Quarter and Full Year 2024 Financial Results and Webcast/Conference Call

Celcuity Transcript: Leerink Global Healthcare Conference 2025

Mar 12, 2025, 9:20 AM EDT - 1 year ago

Celcuity Transcript: Leerink Global Healthcare Conference 2025

Celcuity Transcript: TD Cowen 45th Annual Healthcare Conference

Mar 4, 2025, 10:30 AM EST - 1 year ago

Celcuity Transcript: TD Cowen 45th Annual Healthcare Conference

Celcuity to Participate at Upcoming Cowen and Leerink Investor Conferences

Feb 25, 2025, 7:05 AM EST - 1 year ago

Celcuity to Participate at Upcoming Cowen and Leerink Investor Conferences

SwingTraderPro1
SwingTraderPro1 Jun. 4 at 8:14 PM
$CELC Here’s a classic Bio gap trade setup. Pulled down on the notes offering despite killer breast cancer data, but the offering is now closed. That’s the kind of shakeout that sets up a clean move back up. Keep an eye on July 17 PDUFA as the next catalyst. First target is 100, and if momentum stays, skies are clear well above that. Perfect setup for anyone who loves catching gaps after a shakeout.
0 · Reply
TheTarkioTrader
TheTarkioTrader Jun. 4 at 8:00 PM
$CELC OK it was nice to get all that out-of-the-way..
0 · Reply
ripster47
ripster47 Jun. 4 at 6:40 PM
$CELC ⚡️ Another beautiful Bio Gap Trade Setup vs lows Down on Notes offering with amazing breast cancer data Offering closed we start move back up! Catylyst in July 17 PDUFA for runup Our first target 100 and clear skies over that https://x.com/TenetCharts
0 · Reply
chartistmind
chartistmind Jun. 4 at 2:25 PM
$CELC
0 · Reply
TheTarkioTrader
TheTarkioTrader Jun. 4 at 1:37 PM
$CELC added @$86.37
0 · Reply
TheTarkioTrader
TheTarkioTrader Jun. 4 at 12:38 PM
$CELC
0 · Reply
Uncle_Baby_Billy
Uncle_Baby_Billy Jun. 4 at 11:39 AM
$CELC
0 · Reply
CharlieeMungerTWITS
CharlieeMungerTWITS Jun. 4 at 10:05 AM
$CELC holy crap. $127 and they increased it to $625 million of convertible notes. That tells you there was significant institutional demand for the paper!!! $1B war chest now to commercialize !!
1 · Reply
TheTarkioTrader
TheTarkioTrader Jun. 4 at 7:10 AM
$CELC The market got the details. Upsized to $460M, only 0.25% interest, and a conversion price around $127/share. That’s a meaningful premium to where CELC trades today and suggests strong institutional demand. The financing overhang is largely removed, Oxford debt gets addressed, and the company is funded to advance gedatolisib. Not the terms you’d expect if institutions thought the data wasn’t real.
0 · Reply
Dark_Horse_Investments
Dark_Horse_Investments Jun. 4 at 3:39 AM
$CELC $124.53 coversion price and raising $500 M not $400 M as previously reported. woah what muscling by CEO sullivan ! https://ir.celcuity.com/news-releases/news-release-details/celcuity-inc-announces-pricing-upsized-public-offering-0250
1 · Reply
TheTarkioTrader
TheTarkioTrader Jun. 4 at 12:10 AM
$CELC https://x.com/wassimlaroussi3/status/2061901702219829300?s=61
1 · Reply
TheTarkioTrader
TheTarkioTrader Jun. 3 at 9:46 PM
$CELC It would be nice to hear something tonight if not first thing in the morning. When these deals price quickly, it typically indicates strong institutional demand and a well-covered book. The key is still the conversion price, but faster execution is generally a positive signal that the deal is being absorbed efficiently.
0 · Reply
HappyStockholder
HappyStockholder Jun. 3 at 9:22 PM
$CELC Fireside chat with Brian Sullivan to be conducted at 1:25 tomorrow at the Jeffries Global Healthcare Conference.
0 · Reply
TheTarkioTrader
TheTarkioTrader Jun. 3 at 8:52 PM
$CELC We should hear pricing on the convert within the next 24 48 hours as the book gets built. What the market will focus on is the conversion price. If it comes in only slightly above current levels around 90 to 100 dollars that would likely be viewed as more dilution heavy and could keep pressure on the stock. If it comes in at a meaningful premium roughly 110 to 125 dollars or higher that would suggest strong institutional demand coming off the data and would generally be seen as a more constructive outcome. At this point it is less about the size of the raise and more about where the conversion gets set because that is the real read on how investors are valuing the results.
3 · Reply
TheTarkioTrader
TheTarkioTrader Jun. 3 at 8:45 PM
$CELC Heres what’s next after today’s news. So what happens next is pretty typical for a biotech name: convert deal gets priced, market digests the dilution risk, and the focus shifts back to the actual clinical data. Near-term pressure isn’t unusual after a financing like this, especially after a big move on results.
0 · Reply
TheTarkioTrader
TheTarkioTrader Jun. 3 at 8:40 PM
$CELC Funny how that works… CELC drops strong data yesterday and suddenly today there’s even more cash on the balance sheet. Call it coincidence, call it timing, or call it the “we like our own data enough to finance the next phase” strategy. Either way, the science got stronger and the runway got longer. The market can argue about the rest. 😜
0 · Reply
Lussu1986
Lussu1986 Jun. 3 at 8:39 PM
$CELC https://x.com/bradloncar/status/2061834733307167016/video/1?s=42
1 · Reply
Loudermilk64
Loudermilk64 Jun. 3 at 7:21 PM
$CELC closes green after taking out all the stops?
0 · Reply
TheTarkioTrader
TheTarkioTrader Jun. 3 at 5:52 PM
$CELC Close dialog Craig-Hallum Maintains Buy on Celcuity, Lowers Price Target to $171 BENZINGA
1 · Reply
chartistmind
chartistmind Jun. 3 at 5:46 PM
$CELC starter
1 · Reply
Olivia_Strickland
Olivia_Strickland Jun. 3 at 5:22 PM
$CELC breakout, down 7.0% on 2,233,616 volume. live tape on the rejection: https://tapeboard.com/research/CELC?utm_source=stocktwits&utm_medium=post&utm_campaign=olivia&utm_content=celc-bk-dn-tape&utm_term=research
0 · Reply
CharlieeMungerTWITS
CharlieeMungerTWITS Jun. 3 at 5:01 PM
$CELC According to Celcuity’s most recent quarterly filing (Q1 2026), as of March 31, 2026, the company had: * $387.1 million in cash, cash equivalents, and short-term investments. $55M quarterly cash burn
1 · Reply